Cargando…

Bone Disease in Multiple Myeloma: Pathophysiology and Management

Myeloma bone disease (MBD) is a devastating complication of multiple myeloma (MM). More than 80% of MM patients suffer from destructive bony lesions, leading to pain, fractures, mobility issues, and neurological deficits. MBD is not only a main cause of disability and morbidity in MM patients but al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hameed, Abdul, Brady, Jennifer J, Dowling, Paul, Clynes, Martin, O’Gorman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133035/ https://www.ncbi.nlm.nih.gov/pubmed/25187738 http://dx.doi.org/10.4137/CGM.S16817

Ejemplares similares

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
por: Dowling, Paul, et al.
Publicado: (2014)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Myeloma bone disease: Pathophysiology and management
por: Silbermann, Rebecca, et al.
Publicado: (2013)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
por: Raimondi, Lavinia, et al.
Publicado: (2020)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Pathophysiology and therapeutic advances in myeloma bone disease
por: Zhang, Fujing, et al.
Publicado: (2022)

Multiple Myeloma: A Review of Imaging Features and Radiological Techniques
por: Healy, C. F., et al.
Publicado: (2011)

Pathophysiological Underpinnings of Multiple Myeloma Progression
por: Jagannath, Sungar
Publicado: (2008)

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)

Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Pathophysiological role of calcium channels and transporters in the multiple myeloma
por: Li, Tingting, et al.
Publicado: (2021)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Yeast Mannan-Rich Fraction Modulates Endogenous Reactive Oxygen Species Generation and Antibiotic Sensitivity in Resistant E. coli
por: Smith, Helen, et al.
Publicado: (2022)

Multiple Myeloma Associated Bone Disease
por: Rasch, Stine, et al.
Publicado: (2020)

A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease
por: Ji, Bing, et al.
Publicado: (2015)

Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report
por: Waterhouse, Deirdre F, et al.
Publicado: (2009)

Cellular Mechanisms of Multiple Myeloma Bone Disease
por: Oranger, Angela, et al.
Publicado: (2013)

Advanced Imaging of Multiple Myeloma Bone Disease
por: Hansford, Barry G., et al.
Publicado: (2018)

Osteoblast suppression in multiple myeloma bone disease
por: Adamik, Juraj, et al.
Publicado: (2018)

Pathogenesis and treatment of multiple myeloma bone disease
por: Hiasa, Masahiro, et al.
Publicado: (2021)

Animal Models of Multiple Myeloma Bone Disease
por: Mehdi, Syed Hassan, et al.
Publicado: (2021)

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease
por: Ji, Bing, et al.
Publicado: (2014)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Role of Citrate in Pathophysiology and Medical Management of Bone Diseases
por: Granchi, Donatella, et al.
Publicado: (2019)

An Improved Animal Model of Multiple Myeloma Bone Disease
por: Mehdi, Syed Hassan, et al.
Publicado: (2021)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Managing multiple myeloma
por: Lee, Ann S., et al.
Publicado: (2021)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

Genetic factors influencing the risk of multiple myeloma bone disease
por: Johnson, D C, et al.
Publicado: (2016)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
por: Hengeveld, P J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g26ifh1i1cttmevvdpc3mv586g